Who makes Placebo transdermal one 90 μL spray?

Placebo transdermal one 90 μL spray is developed by Lumara Health, Inc..

What development phase is Placebo transdermal one 90 μL spray in?

Placebo transdermal one 90 μL spray is in Phase 3.

Last reviewed 2026-04-23 · How we verify

Placebo transdermal one 90 μL spray

Lumara Health, Inc. · Phase 3 active Small molecule

A placebo transdermal spray that delivers no active pharmaceutical ingredient, used as a control in clinical trials.

At a glance

Generic name	Placebo transdermal one 90 μL spray
Sponsor	Lumara Health, Inc.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Placebo formulations serve as inactive comparators in randomized controlled trials to establish the efficacy and safety of investigational drugs by accounting for natural disease progression and psychological effects. This particular placebo is administered as a 90 μL transdermal spray, matching the delivery method of the active comparator drug being studied in the phase 3 trial.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo transdermal one 90 μL spray CI brief — competitive landscape report
Placebo transdermal one 90 μL spray updates RSS · CI watch RSS
Lumara Health, Inc. portfolio CI